Session 4: Health & Wellness Title: The Changing Face Of Healthcare: Where Are The Opportunities? Dr Jeff Wager, Artisan Pharma

1. CEO’s Life Sciences Conference “Innovation Without Borders” Sheraton Imperial Hotel, Kuala Lumpur, Malaysia October 6 th and 7 th 2009 Non-Confidential

5. Summary of Clinical Experience with ART-123 (as of Sep 30, 2009) Study Region Sponsor Indication # of subjects Phase 1 Japan Asahi Kasei Pharma (AKP) - 20 Early Phase 2 Disseminated intravascular coagulation (DIC) 12 Late Phase 2 90 Phase 3 116 Post marketing surveillance 1,243 Phase 2b (ongoing) World-wide Artisan DIC in sepsis 541 Phase 1 USA AKP - 55 Phase 2 USA/Canada Deep vein thrombosis (DVT) 312 Total 2,389

6. Global Thought-Leaders in Critical Care, DIC/Sepsis and Thrombomodulin Support ART 123 Professor of Emergency and Critical Care Medicine, lead investigator of ART 123 Japanese 3 study Keio University Tokyo, Japan Prof. Naoki Aikawa, M.D., DMSc, F.A.C.S. Ex-Medical Director for Lilly in charge of Xigris; ex-Vice President of Novo Nordisk, Inc. Chief Scientific Officer Sangart, Inc. Howard Levy, MD Extensive research on pathophysiology of thrombotic and cardiovascular disorders and their pharmacologic management Loyola University Med. Center Chicago, IL Jawad Fareed, Ph.D. Extensive research in thromboembolism and hematology McMaster University Hamilton, Ontario Mark A. Crowther M.D., M.Sc., F.R.C.P.C. Research on the regulation of blood clotting with a special emphasis on the role of blood vessel proteins, including thrombomodulin, in controlling clot formation Oklahoma Med. Res. Found. Oklahoma City, OK Charles T. Esmon, Ph.D. Leading clinician and researcher in cardiovascular disease and critical care medicine Cooper University Camden, NJ Joseph E. Parrillo, M.D. Author of Xigris NEJM publication and author of Xigris cost-effectiveness paper University of Brussels Belgium Jean-Louis Vincent, M.D., Ph.D. Author of retrospective analysis of Xigris for DIC and NEJM DIC review; experimental and clinical studies on the interaction of infection/inflammation and hemostasis University of Amsterdam Netherlands Marcel Levi, M.D., Ph.D. Xigris external consultant; lead author of Xigris NEJM publication; author of Xigris cost-effectiveness paper; extensive research in sepsis and pulmonary disease Vanderbilt University Nashville, TN Gordon Bernard, M.D. Relevant Background Location Member

8. Estimated DIC in Sepsis Patients in Asia Pacific Nations Licensed to Artisan